FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Pharmaceutically Acceptable Salt topics
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Dimethyl Fumarate
Amelioration
Benzimidazole
Antiviral Agents
Hepatitis C Virus
Antiviral Agent
Antivirals
Hepatitis C
Diabetic Complications
Complication
Kidney Disease
Pyridoxamine
Neurodegenerative Disease

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Pharmaceutically Acceptable Salt patents



      
           
This page is updated frequently with new Pharmaceutically Acceptable Salt-related patents. Subscribe to the Pharmaceutically Acceptable Salt RSS feed to automatically get the update: related Pharmaceutically RSS feeds.

Subscribe to updates on this page: Pharmaceutically Acceptable Salt RSS RSS

Date/App# patent app List of recent Pharmaceutically Acceptable Salt-related patents
04/17/14
20140107166
 Histone deacetylase inhibitors and methods of use thereof patent thumbnailHistone deacetylase inhibitors and methods of use thereof
The present invention provides novel compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of a compound of the invention to a subject in need thereof.
04/17/14
20140107164
 Arylvinylazacycloalkane compounds and methods of preparation and use thereof patent thumbnailArylvinylazacycloalkane compounds and methods of preparation and use thereof
Novel vinylazacycloalkane compounds of formula (i) are disclosed. The compounds are ligands of various nachrs.
04/17/14
20140107151
 Tyrosine kinase inhibitors patent thumbnailTyrosine kinase inhibitors
The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, jak3, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts..
04/17/14
20140107150
 New compounds ii patent thumbnailNew compounds ii
And their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or n-oxides, which are inhibitors of ssao activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of ssao activity is beneficial, such as such as inflammatory diseases and immune disorders..
04/17/14
20140107141
 Kinase inhibitors and methods of use thereof patent thumbnailKinase inhibitors and methods of use thereof
The present invention provides compounds of formula i, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., gsk3 (e.g., gsk3α or gsk3β) or ck1) activity.
04/17/14
20140107134
 Compounds for inflammation and immune-related uses patent thumbnailCompounds for inflammation and immune-related uses
Or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein x, y, a, z, l and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders..
04/17/14
20140107133
 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide patent thumbnail3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide
Or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (copd), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.. .
04/17/14
20140107132
 Substituted pyridine compounds for inflammation and immune-related uses patent thumbnailSubstituted pyridine compounds for inflammation and immune-related uses
Or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.. .
04/17/14
20140107131
 Pyrazolylaminopyridines as inhibitors of fak patent thumbnailPyrazolylaminopyridines as inhibitors of fak
Or a pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r11, r12, r13, q, z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers..
04/17/14
20140107127
 Pyrazinoisoquinoline compounds patent thumbnailPyrazinoisoquinoline compounds
This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
04/17/14
20140107126
Novel inhibitor compounds of phosphodiesterase type 10a
The compounds of the formula i, the n-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10a and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.. .
04/17/14
20140107120
Dual-acting benzoimidazole antihypertensive agents
Wherein: ar, r, n, x, r2-3 and r5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.
04/17/14
20140107115
Novel immune system modulators
The present invention relates to a compound of formula i: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.. .
04/17/14
20140107107
Pharmaceutical formulation containing thienotriazolodiazepine compounds
Wherein x is a halogen, r1 is c1-c4 alkyl, r2 is c1-c4 alkyl, a is an integer of 1-4, r3 is c1-c4 alkyl, c1-c4 hydroxyalkyl, c1-c4 alkoxy, phenyl optionally having substituent(s), or heteroaryl optionally having substituent(s), a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hpmcas.
04/17/14
20140107102
Ocular allergy treatments
Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.. .
04/17/14
20140107100
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
The invention is directed 10 compound's of formula i: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.. .
04/17/14
20140107099
Pyrazolopyrimidine jak inhibitor compounds and methods
The invention provides jak kinase inhibitors of formula ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein r1, r2, r7 and z are defined herein, a pharmaceutical composition that includes a compound of formula ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a jak kinase activity in a patient.. .
04/17/14
20140107093
Compounds useful as inhibitors of atr kinase
Or a pharmaceutically acceptable salt, wherein the variables are as defined herein.. .
04/17/14
20140107084
Ultra low dose doxepin and methods of using the same to treat sleep disorders
The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .
04/17/14
20140107073
Gdf-8 inhibitors
And pharmaceutically acceptable salts thereof, wherein n, r1, r2, r5, r6, x and z are defined herein. Also provided are pharmaceutical compositions comprising the same.
04/17/14
20140107051
Isoflavones for treating mucopolysaccharidoses
A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (i), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (i), a derivative thereof, or a pharmaceutically acceptable salt thereof..
04/17/14
20140107038
Method for administering omega-conopeptide
The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.
04/17/14
20140105979
Compositions and methods for the transdermal delivery of methylphenidate
Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate.
04/17/14
20140105976
Pharmaceutical formulations of pilocarpine
Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof; and a coating layer comprising a coating polymer.. .
04/17/14
20140105973
Method of treating a disease condition susceptible to baclofen therapy
The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.. .
04/17/14
20140105859
Modulators of pharmacokinetic properties of therapeutics
Or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.. .
04/10/14
20140100537
Transdermal pharmaceutical preparation and administration of tirofiban
The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition.
04/10/14
20140100369
Pyrrolopyridines as kinase inhibitors
Compounds of formula i are useful for inhibition of chk1 and/or chk2. Methods of using compounds of formula i and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed..
04/10/14
20140100366
Process for making thienopyrimidine compounds
And stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof.. .
04/10/14
20140100246
Aclidinium for use in improving the quality of sleep in respiratory patents
The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.. .
04/10/14
20140100232
Combination treatment for rosacea
The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier..
04/10/14
20140100231
Non-nucleoside reverse transcriptase inhibitors
Are hiv reverse transcriptase inhibitors, wherein r1, r2, re, l, m and z are defined herein. The compounds of formula i and their pharmaceutically acceptable salts are useful in the inhibition of hiv reverse transcriptase, the prophylaxis and treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.
04/10/14
20140100223
Compounds and methods for the treatment of isocitrate dehydrogenase related diseases
The invention relates to compounds of formula i or a pharmaceutically acceptable salt, ester or prodrug thereof:. .
04/10/14
20140100218
Treatment of mild and moderate alzheimer's disease
The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“compound i”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of alzheimer's type, diabetes, insomnia, and other indications.
04/10/14
20140100179
Novel urea compounds
Or a pharmaceutically acceptable salt thereof.. .
04/10/14
20140099283
2'-chloro nucleoside analogs for hcv infection
Or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein b, z and pd are as described herein.. .
04/03/14
20140094522
Compound formulations of 2-amino-1, 3-propanediol compounds
Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided.. .
04/03/14
20140094498
Methods and compositions for treating post-operative pain comprising clonidine
The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.. .
04/03/14
20140094491
Dimethyl-benzoic acid compounds
Or a pharmaceutically acceptable salt thereof.. .
04/03/14
20140094489
Heterocyclic carboxylic acid ester derivative
Or a pharmaceutically acceptable salt thereof.. .
04/03/14
20140094482
Benzazocine-ring compound inhibition of tau hyperphosphorylation
A method of inhibiting hyperphosphorylation of the tau protein and/or a tlr4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a flna-binding effective amount of a flna-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin a (flna) of seq id no: 1.
04/03/14
20140094474
Androgen receptor modulating carboxamides
Wherein rx, rz, r9, r10, r14, r14′, r15, r15′, a and b are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (sarm) and are useful as medicaments in the treatment of prostate cancer and other ar dependent conditions and diseases where ar antagonism is desired..
04/03/14
20140094473
Inhibitors of influenza viruses replication
Or a pharmaceutically acceptable salt thereof, wherein the values of structural formula (i) are as described herein. A compound is represented by structural formula (i) or a pharmaceutically acceptable salt thereof, wherein the values of structural formula (i) are as described herein.
04/03/14
20140094470
Combination treatment for dermatological conditions
The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier..
04/03/14
20140094459
Tyrosine kinase inhibitors
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof..
04/03/14
20140094454
Tetrahydropyrrolothiazine compounds
Or a pharmaceutically acceptable salt thereof.. .
04/03/14
20140094449
Treatment of bipolar disorder
The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (impase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of formula (i), or is a pharmaceutically acceptable salt thereof; formula (i); in which: e is s or se and each of phenyl rings a and b is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from f, cl and br; (2) c1-c4 alkyl, such as c1-c2 alkyl or c1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from f, cl and br; and (3) c1-c4 alkoxy, such as c1-c2 alkoxy or c1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from f, cl and br.. .
04/03/14
20140094447
Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam..
04/03/14
20140094446
Cyclic amino acids for the treatment of pain
Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said compositions are for use in the treatment of pain.
04/03/14
20140094443
Tgr5 modulators and methods of use thereof
Or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of formula a are tgr5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation..
04/03/14
20140094435
Use of dextran sulfate
A method of inhibiting instant blood-mediated inflammatory reaction (ibmir) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient.
04/03/14
20140094405
Cholesterol derivatives of inhibitors of viral fusion
The present invention relates to compounds comprising at least ten contiguous amino acids of the hr2 domain of a type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the c-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus..
04/03/14
20140094403
Enopeptins, uses thereof, and methods of synthesis thereto
Provided herein are inventive enopeptin compounds of formula (i): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment..
04/03/14
20140094402
Lantibiotic nai-802, pharmaceutically acceptable salts, compositions and uses thereof
The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents.. .


Popular terms: [SEARCH]

Pharmaceutically Acceptable Salt topics: Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Dimethyl Fumarate, Amelioration, Benzimidazole, Antiviral Agents, Hepatitis C Virus, Antiviral Agent, Antivirals, Hepatitis C, Diabetic Complications, Complication, Kidney Disease, Pyridoxamine, Neurodegenerative Disease

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Pharmaceutically Acceptable Salt for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pharmaceutically Acceptable Salt with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2224

5256

1 - 1 - 77